Describe a practical approach to evaluating a patient with suspected androgenetic alopecia, including history, examination, and initial pharmacologic options.

Describe a practical approach to evaluating a patient with suspected androgenetic alopecia, including history, examination, and initial pharmacologic options.

• A. Begin finasteride for all patients immediately.
• B. Order broad laboratory tests for all hormones and ignore family history.
• C. Focus on cosmetic considerations only; ignore pharmacotherapy.
• D. Assess pattern of hair loss and family history; review medications and hormonal factors; perform scalp examination/trichoscopy; discuss first-line options such as minoxidil and consider finasteride for men after discussing risks and pregnancy precautions.

Answer: (D)

The main idea is to integrate history with a targeted scalp examination to confirm androgenetic alopecia and then start safe, evidence-based treatment. People often notice a gradual, patterned thinning that runs in families, and AGA is driven by androgens degrading hair follicle size over time. Because of this, a thoughtful history should cover when the thinning began, how it progressed, any medications or hormonal factors that could contribute, and whether there is a family history of similar thinning. The exam should look for the characteristic pattern: men typically show recession at the temples with vertex thinning, while women usually have diffuse thinning on the crown with a relatively preserved frontal hairline. Scalp examination and, if available, trichoscopy can reveal follicular miniaturization and other clues that support AGA and help rule out inflammatory or scarring causes. In terms of treatment, begin with first-line, evidence-based pharmacology. Topical minoxidil is the go-to option for both men and women; it helps lengthen the anagen phase and increases hair diameter modestly, often improving visible fullness with consistent use. For men who are appropriate candidates, finasteride—a 5-alpha reductase inhibitor that lowers dihydrotestosterone (DHT) levels in the scalp—can be added or used when a patient is well informed about potential risks. It’s important to discuss sexual side effects and other risks, and for women of childbearing potential, pregnancy precautions must be highlighted because finasteride can be teratogenic. This approach combines a clear diagnostic process with practical, early pharmacologic management. Broad laboratory testing is not routinely required for every patient with suspected androgenetic alopecia and is reserved for cases where other signs point to a non-AGA cause (such as thyroid disease, iron deficiency, or other hormonal disorders). The emphasis remains on history and exam to guide initial therapy.

The main idea is to integrate history with a targeted scalp examination to confirm androgenetic alopecia and then start safe, evidence-based treatment. People often notice a gradual, patterned thinning that runs in families, and AGA is driven by androgens degrading hair follicle size over time. Because of this, a thoughtful history should cover when the thinning began, how it progressed, any medications or hormonal factors that could contribute, and whether there is a family history of similar thinning. The exam should look for the characteristic pattern: men typically show recession at the temples with vertex thinning, while women usually have diffuse thinning on the crown with a relatively preserved frontal hairline. Scalp examination and, if available, trichoscopy can reveal follicular miniaturization and other clues that support AGA and help rule out inflammatory or scarring causes.

In terms of treatment, begin with first-line, evidence-based pharmacology. Topical minoxidil is the go-to option for both men and women; it helps lengthen the anagen phase and increases hair diameter modestly, often improving visible fullness with consistent use. For men who are appropriate candidates, finasteride—a 5-alpha reductase inhibitor that lowers dihydrotestosterone (DHT) levels in the scalp—can be added or used when a patient is well informed about potential risks. It’s important to discuss sexual side effects and other risks, and for women of childbearing potential, pregnancy precautions must be highlighted because finasteride can be teratogenic. This approach combines a clear diagnostic process with practical, early pharmacologic management.

Broad laboratory testing is not routinely required for every patient with suspected androgenetic alopecia and is reserved for cases where other signs point to a non-AGA cause (such as thyroid disease, iron deficiency, or other hormonal disorders). The emphasis remains on history and exam to guide initial therapy.